8-K: Surgery Partners Stockholders Re-Elect Directors, Approve 2025 Omnibus Incentive Plan at Annual Meeting

Surgery Partners, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all proposals, including the re-election of Class I directors and the approval of the 2025 Omnibus Incentive Plan, were passed.

Summary

• Surgery Partners, Inc. held its Annual Meeting of Stockholders on June 6, 2025.
• As of the record date, April 8, 2025, 128,192,739 shares of common stock were outstanding and entitled to vote.
• Stockholders re-elected John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt as Class I directors to serve until the 2028 annual meeting.
• The advisory vote on executive compensation was approved on a non-binding basis, with 96,577,058 votes for and 19,241,638 votes against.
• The 2025 Omnibus Incentive Plan was approved by stockholders, with 101,740,477 votes for and 13,957,369 votes against.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025 was ratified with 122,065,302 votes for.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposed items, including director re-elections and the new incentive plan, were approved by stockholders, indicating stable corporate governance and alignment with management's proposals.

Positives

• All three Class I director nominees (John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt) were successfully re-elected, ensuring continuity in leadership.
• The non-binding advisory vote on executive compensation passed, indicating stockholder support for the company's current executive compensation practices.
• The 2025 Omnibus Incentive Plan was approved, providing the company with a framework for future equity-based compensation to attract and retain talent.
• The ratification of Ernst & Young LLP as the independent auditor for fiscal year 2025 demonstrates continued confidence in the company's financial oversight.

Future Outlook

The approval of the 2025 Omnibus Incentive Plan provides a mechanism for future equity-based compensation, which can support talent retention and alignment with stockholder interests. The re-election of directors ensures continuity in the board's strategic oversight through 2028.

Industry Context

This 8-K filing primarily details the outcomes of a routine annual stockholder meeting, which is a standard corporate governance event for publicly traded companies. The approval of an omnibus incentive plan is a common practice to manage long-term employee and executive compensation in the healthcare services industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Approved all proposals, including the re-election of directors and the 2025 Omnibus Incentive Plan, indicating support for current governance and compensation strategies.
• Employees: Potential beneficiaries of the newly approved 2025 Omnibus Incentive Plan, which can offer equity-based compensation.

Next Steps

• The re-elected Class I directors will serve until the 2028 annual meeting of stockholders.
• The 2025 Omnibus Incentive Plan is now effective and can be utilized for compensation purposes.
• Ernst & Young LLP will serve as the independent registered public accounting firm for fiscal year 2025.

Key Dates

Keywords

Surgery Partners, SGRY, Annual Meeting, Stockholders, Corporate Governance, Omnibus Incentive Plan, Executive Compensation, Director Election, Auditor Ratification, SEC Filing, 8-K